786 related articles for article (PubMed ID: 19048779)
1. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
2. Applications of high-throughput ADME in drug discovery.
Kassel DB
Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
[TBL] [Abstract][Full Text] [Related]
3. Hit discovery and hit-to-lead approaches.
Keseru GM; Makara GM
Drug Discov Today; 2006 Aug; 11(15-16):741-8. PubMed ID: 16846802
[TBL] [Abstract][Full Text] [Related]
4. [The discovery process in the pharmaceutical industry].
Scatton B
J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
[TBL] [Abstract][Full Text] [Related]
5. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
6. Selection criteria for drug-like compounds.
Muegge I
Med Res Rev; 2003 May; 23(3):302-21. PubMed ID: 12647312
[TBL] [Abstract][Full Text] [Related]
7. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
[TBL] [Abstract][Full Text] [Related]
8. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
Beaumont K; Smith DA
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
[TBL] [Abstract][Full Text] [Related]
9. ChemGPS-NP: tuned for navigation in biologically relevant chemical space.
Larsson J; Gottfries J; Muresan S; Backlund A
J Nat Prod; 2007 May; 70(5):789-94. PubMed ID: 17439280
[TBL] [Abstract][Full Text] [Related]
10. Compound scale-up at the discovery-development interface.
Nikitenko AA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
[TBL] [Abstract][Full Text] [Related]
11. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment.
Showalter HD; Denny WA
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S3-17. PubMed ID: 18762151
[TBL] [Abstract][Full Text] [Related]
12. The hit-to-lead process at Schering AG: strategic aspects.
Steinmeyer A
ChemMedChem; 2006 Jan; 1(1):31-6. PubMed ID: 16892330
[TBL] [Abstract][Full Text] [Related]
13. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
[TBL] [Abstract][Full Text] [Related]
14. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
15. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
16. Natural product hybrids as new leads for drug discovery.
Tietze LF; Bell HP; Chandrasekhar S
Angew Chem Int Ed Engl; 2003 Sep; 42(34):3996-4028. PubMed ID: 12973759
[TBL] [Abstract][Full Text] [Related]
17. [Strategy of molecular drug design: activity and druggability].
Guo ZR
Yao Xue Xue Bao; 2010 May; 45(5):539-47. PubMed ID: 20931752
[TBL] [Abstract][Full Text] [Related]
18. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
Lüpfert C; Reichel A
Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
[TBL] [Abstract][Full Text] [Related]
19. Pursuing the leadlikeness concept in pharmaceutical research.
Hann MM; Oprea TI
Curr Opin Chem Biol; 2004 Jun; 8(3):255-63. PubMed ID: 15183323
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided fragment screening for lead discovery.
Verdonk ML; Hartshorn MJ
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):404-10. PubMed ID: 15338949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
